Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.
about
Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccineImpaired binding of standard initiation factors mediates poliovirus translation attenuation.The Spatial Dynamics of Poliomyelitis in the United States: From Epidemic Emergence to Vaccine-Induced Retreat, 1910–1971Immunology of Gut Mucosal VaccinesAntibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trialA poliovirus hybrid expressing a neutralization epitope from the major outer membrane protein of Chlamydia trachomatis is highly immunogenic.Live attenuated AIDS viruses as vaccines: promise or peril?Live attenuated Salmonella: a paradigm of mucosal vaccines.Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region.Genetic basis for immunological aberrations in poliovirus Sabin serotype 3 strains imported in the netherlands.Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications.Mechanisms of genetic variation in polioviruses.Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries.Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccinesHuman enteroviruses are not the cause of neurological impairments in children at the Korle-Bu Teaching HospitalEvolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitisCoxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strainAttenuating mutations in the poliovirus 5' untranslated region alter its interaction with polypyrimidine tract-binding protein.Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicityPoliomyelitis: eradication in sightOral administration of live virus protects susceptible mice from developing Theiler's virus-induced demyelinating disease.Patterns of polyomavirus SV40 infections and associated cancers in humans: a modelHigh diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitisFormalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses.Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya.Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routesConstruction of a poliovirus type 1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II.The Sabin live poliovirus vaccination trials in the USSR, 1959The poliomyelitis story: a scientific hegiraRetrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the futureImmunisation policies--successes, failures and the future.Progress in genetics and genomics of nonhuman primates. IntroductionCorrelation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.Future of polio vaccines.Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3.Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains.Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?
P2860
Q21562177-0AD1024B-3047-44C0-9C43-9B43AB80EC98Q24540531-9985B9C9-1B8F-4461-ABD6-172544712949Q24546210-8E2C91F1-A4CF-4AFD-AACA-819DDC0AC94CQ28972559-69F45B29-D3B6-4A8A-AD90-A332C4F588A6Q30532861-0291FB52-2919-4FEF-B082-06F1E5D16C1BQ33611894-703A0683-9CA2-402E-A6A5-09767AD2DEE3Q33776149-91FA53E0-95EB-43E7-9654-DA6AA72794E1Q33784947-DB45F810-A009-4035-A761-06D338F4DA1DQ33804871-D193F900-312A-41B6-A18E-261A50E88736Q33961832-664CDF4E-3810-42FC-9651-AB0BCC9F1903Q33970483-CB899B63-49B5-4ECC-BBB9-873BFAA80EF0Q34143845-F1D485BC-FC34-4E77-8EE8-8349DD41BC0BQ34283940-B2E8518C-64D2-4394-A578-EB02C1755A58Q34358949-D6DDB122-E999-4996-98CA-12A747B3E978Q34563993-7074F09D-E8F9-4DC9-92DC-BBDDA647DE12Q34743074-FBE9F2EA-E4E9-4495-BE05-41D51343CCD8Q35764808-03474F93-C955-47C1-A633-772C5C1FC654Q35883492-DACE1997-4C5A-4D3D-A1EF-2BB054EB1195Q35896058-77141C39-6032-4BEE-8467-75CDE4497F02Q35915233-DB88E53D-5C6E-43DB-85AA-B2F2BFD291D1Q36069746-506F50B4-D682-40CE-837E-43830641B130Q36173844-460DEDD3-5105-4395-A4A9-2C4123F1C1AFQ36637959-5C72B536-91A1-4AD5-97C4-542D8A7C03F1Q36649875-F9FC6E7F-67D2-4F16-8E71-FFC9504212EBQ36669305-1180A0E7-73C4-4E99-A9AB-4A90A58986BAQ36760192-752360E3-B8D5-4A48-9DA5-FDFD1F6CB3EBQ36832245-E2E90A3B-2868-4D13-89A6-F050712AB1B4Q36988322-73205624-3335-4A21-AE95-0E4569DA90EFQ36988892-9506BD5C-F702-463C-B240-EDCC69A0C9B7Q37060273-CE96E4D8-3D8C-427A-8CAC-EF12BB589EC2Q37219942-6F91CD63-BDF4-49DD-A4DF-6919BB839A55Q37271232-A8E65E69-0744-441C-BCD9-B8561CA1F7B7Q37362294-6984ABAE-DE11-4F13-A70C-0BC3981C22E1Q37450453-D1DD0033-4E92-4A71-A05D-AF76AC119CB4Q37567834-67EB3195-9FEF-4491-B1C5-E39A5F637786Q37878482-6612FD6A-CB8B-41AE-9F6A-628B021CC785Q38028997-A9DA08B1-D3B1-4430-8231-BCA0A52DFC9FQ38162948-945C6C4B-7124-4A98-8B67-4A41C796671BQ38186768-B929EDCF-8AAD-45AB-B65A-605C52737317Q38212516-6D470E52-D8F5-46CB-A74D-135C7B30F69A
P2860
Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Oral poliovirus vaccine: histo ...... poliomyelitis from the world.
@en
Oral poliovirus vaccine: histo ...... poliomyelitis from the world.
@nl
type
label
Oral poliovirus vaccine: histo ...... poliomyelitis from the world.
@en
Oral poliovirus vaccine: histo ...... poliomyelitis from the world.
@nl
prefLabel
Oral poliovirus vaccine: histo ...... poliomyelitis from the world.
@en
Oral poliovirus vaccine: histo ...... poliomyelitis from the world.
@nl
P356
P1476
Oral poliovirus vaccine: histo ...... poliomyelitis from the world.
@en
P2093
P304
P356
10.1093/INFDIS/151.3.420
P407
P577
1985-03-01T00:00:00Z